Table 1.
TMPRSS2–ERG rearrangement findings in prostatic small cell carcinoma and concurrent acinar adenocarcinoma
| Case | Small cell carcinoma | Concurrent adenocarcinoma |
|---|---|---|
| 1 | Negative | Negative |
| 2 | Negative | Negative |
| 3 | ERG–TMPRSS2 fusion | ERG–TMPRSS2 fusion |
| 4 | ERG–TMPRSS2 fusion, loss ERG 5′ | ERG–TMPRSS2 fusion, loss ERG 5′ |
| 5 | Negative | Negative |
| 6 | ERG–TMPRSS2 fusion | ERG–TMPRSS2 fusion |
| 7 | ERG–TMPRSS2 fusion | |
| 8 | Negative | |
| 9 | ERG–TMPRSS2 fusion | |
| 10 | Negative | |
| 11 | ERG–TMPRSS2 fusion | |
| 12 | ERG–TMPRSS2 fusion, gain of 21q | ERG–TMPRSS2 fusion, gain of 21q |
| 13 | Negative | |
| 14 | ERG–TMPRSS2 fusion | ERG–TMPRSS2 fusion |
| 15 | ERG–TMPRSS2 fusion | ERG–TMPRSS2 fusion |
| 16 | Negative | ERG–TMPRSS2 fusion, gain of 21q |
| 17 | ERG–TMPRSS2 fusion, gain of 21q | ERG–TMPRSS2 fusion, gain of 21q, loss ERG 5′ |
| 18 | ERG–TMPRSS2 fusion, loss ERG 5′ | ERG–TMPRSS2 fusion, loss ERG 5′ |
| 19 | ERG–TMPRSS2 fusion | |
| 20 | Negative | |
| 21 | Negative | |
| 22 | ERG–TMPRSS2 fusion | |
| 23 | Negative | Negative |
| 24 | Negative, gain of 21q | |
| 25 | Negative | |
| 26 | ERG–TMPRSS2 fusion | |
| 27 | Negative | |
| 28 | Negative, gain of 21q | |
| 29 | Negative | |
| 30 | Negative |